Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Double Blind, Randomized, Placebo Controlled, Maximal Dose Study to Determine the Safety, Tolerability of Topical Cream Containing MGC (Medical Grade Cannabis) in Healthy Volunteers

Next Previous
Trial Profile

A Phase I, Double Blind, Randomized, Placebo Controlled, Maximal Dose Study to Determine the Safety, Tolerability of Topical Cream Containing MGC (Medical Grade Cannabis) in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Psoriasis
  • Focus Adverse reactions
  • Sponsors One World Cannabis

Most Recent Events

  • 30 Jan 2019 Results presented in an OWC Pharmaceutical Research Corp Media Release.
  • 30 Jan 2019 According to an OWC Pharmaceutical Research Corp media release, this study was conducted between September 2017 when the first subject entered the study and January 2019 when the last subjected completed the study.
  • 30 Jan 2019 Status changed from recruiting to completed, according to an OWC Pharmaceutical Research Corp media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top